Marieke Pape

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 11

Top Topics

Small Cell Lung Cancer

Top Venues

International journal of cancer

Therapeutic advances in medical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Marieke Pape, Pauline A J Vissers, Willemieke P M Dijksterhuis, David Bertwistle, Laura McDonald, Bianca Mostert, Sarah Derks, Irma M Oving, Rob H A Verhoeven, Hanneke W M van Laarhoven
Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study. Therapeutic advances in medical oncology 15 (2023)
Marieke Pape, Steven C Kuijper, Pauline A J Vissers, Jelle P Ruurda, Karen J Neelis, Hanneke W M van Laarhoven, Rob H A Verhoeven
Conditional relative survival in non-metastatic esophagogastric cancer between 2006 and 2020: a population-based study. International journal of cancer (2023)
Anouk Rijken, Marieke Pape, Geert A Simkens, Ignace H J T de Hingh, Misha D P Luyer, Johanna W van Sandick, Hanneke W M van Laarhoven, Rob H A Verhoeven, Felice N van Erning
Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival. International journal of cancer (2023)
Marieke Pape, Pauline A J Vissers, Willemieke P M Dijksterhuis, David Bertwistle, Laura McDonald, Bianca Mostert, Sarah Derks, Irma M Oving, Rob H A Verhoeven, Hanneke W M van Laarhoven
Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study. Therapeutic advances in medical oncology 15 (2023)
Steven C Kuijper, Marieke Pape, Pauline A J Vissers, Paul M Jeene, Ewout A Kouwenhoven, Nadia Haj Mohammad, Jelle P Ruurda, Meindert N Sosef, Rob H A Verhoeven, Hanneke W M van Laarhoven
Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: A population-based study. International journal of cancer (2023)
Steven C Kuijper, Marieke Pape, Pauline A J Vissers, Paul M Jeene, Ewout A Kouwenhoven, Nadia Haj Mohammad, Jelle P Ruurda, Meindert N Sosef, Rob H A Verhoeven, Hanneke W M van Laarhoven
Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: a population-based study. International journal of cancer (2023)
Marieke Pape, Steven C Kuijper, Pauline A J Vissers, Jelle P Ruurda, Karen J Neelis, Hanneke W M van Laarhoven, Rob H A Verhoeven
Conditional relative survival in nonmetastatic esophagogastric cancer between 2006 and 2020: A population-based study. International journal of cancer (2023)
Marieke Pape, Pauline A J Vissers, Judith de Vos-Geelen, Maarten C C M Hulshof, Suzanne S Gisbertz, Paul M Jeene, Hanneke W M van Laarhoven, Rob H A Verhoeven
Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population-based study. Cancer science 113 (3) (2022)
Marieke Pape, Pauline A J Vissers, David Bertwistle, Laura McDonald, Marije Slingerland, Nadia Haj Mohammad, Laurens V Beerepoot, Jelle P Ruurda, Grard A P Nieuwenhuijzen, Paul M Jeene, Hanneke W M van Laarhoven, Rob H A Verhoeven
A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma. Therapeutic advances in medical oncology 14 (2022)
Marieke Pape, Pauline A J Vissers, Laurens V Beerepoot, Mark I van Berge Henegouwen, Sjoerd M Lagarde, Stella Mook, Markus Moehler, Hanneke W M van Laarhoven, Rob H A Verhoeven
A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577. Therapeutic advances in medical oncology 14 (2022)
Steven C Kuijper, Marieke Pape, Nadia Haj Mohammad, Theo van Voorthuizen, Rob H A Verhoeven, Hanneke W M van Laarhoven
SOURCE beyond first-line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first-line palliative systemic therapy. International journal of cancer (2022)